Uncategorized
Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today reported financial results for the first quarter ended March 31, 2019, along with a general business update. Aerie Highlights The Rocklatan® (netarsudil and latanoprost ophthalmic solution)